What's happening
This bill establishes a state-run generic drug lab and production facility, prioritizing affordable insulin, to lower prescription drug costs.
Why it matters
Creates a public option for generic drug manufacturing. by having the state directly produce and distribute generics (starting with insulin), it introduces price competition and may pressure private manufacturers to lower their own prices.
Caps insulin costs for residents. the bill sets a maximum price of $30 per monthly dose of insulin for New York residents, directly protecting patients from high out-of-pocket expenses.
Focuses on drug shortages and public health needs. the state facility will prioritize drugs that are most needed to lower costs, address shortages, and improve public health, potentially filling critical gaps when private sector supply is insufficient.
Allows flexibility and speed through partnerships. before the state’s facility is fully operational, the Department of Health can partner with nonprofits or other entities to quickly bring lower-cost insulin to market, aiming for immediate relief rather than waiting for state infrastructure to be built.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Headline styles
Make Generic Insulin in NY
Plain English, a few words. Used as the page title.
Sponsors
No co-sponsors yet.
History
- Referred to health
Full text
2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
9535
IN ASSEMBLY
March 20, 2024
Introduced by M. of A. STECK -- read once and referred to the Committee on Health
AN ACT to amend the public health law, in relation to establishing a generic drug research and development laboratory and production facility and the empire state biosimilar insulin initiative
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. Article 2-A of the public health law is amended by adding a new title IV to read as follows:
TITLE IV
NEW YORK AFFORDABLE DRUG MANUFACTURING ACT Section 285. Definitions.
286. Generic drug research and development laboratory and
production facility; empire state biosimilar insulin
initiative.
287. Partnerships; production and distribution of prescription
drugs.
288. Proprietary information.
§ 285. Definitions. 1. For the purposes of this title, the following terms shall have the following meanings:
(a) "Generic drug" shall mean a drug that is approved pursuant to subdivision (j) of section 355 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Sec. 301 et seq.), or a biosimilar, as defined under the federal Public Health Service Act (42 U.S.C. Sec. 262).
(b) "Partnerships" shall include, but not be limited to, agreements for the procurement of generic prescription drugs by way of contracts or purchasing by a payer, state governmental agency, group purchasing organization, nonprofit organization, or other entity.
§ 286. Generic drug research and development laboratory and production facility; empire state biosimilar insulin initiative. 1. (a) The department shall establish a generic drug research and development laboratory and production facility within the university of the state of New York system.
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD13501-01-3
(b) The generic drug research and development laboratory and production facility established pursuant to paragraph (a) of this subdivision shall produce and distribute generic prescription drugs, with the intent that these drugs be made widely available to public and private purchasers, facilities licensed pursuant to article twenty-eight of this chapter, and pharmacies as defined in section six thousand eight hundred two of the education law, as appropriate.
(c) Each drug produced pursuant to paragraph (b) of this subdivision shall be made available to providers, patients, and purchasers at a price not to exceed the cost of such production for residents of the state.
(d) The department shall prioritize the development and production of generic prescription drugs that have the greatest impact on lowering drug costs to patients, increasing competition and addressing shortages in the prescription drug market, improving public health, or reducing the cost of prescription drugs to public and private purchasers.
2. The first initiative of the generic drug research and development laboratory and production facility established pursuant to subdivision one of this section shall be the empire state biosimilar insulin initiative. Such initiative shall include the research, development, and production of generic forms of the three most widely used forms of insulin. Such insulin shall be produced or distributed by a non-profit generic drug manufacturer that is registered with the United States Food and Drug Administration.
3. Until such time as the generic drug research and development laboratory and production facility is completed and the empire state biosimilar insulin initiative begins, the commissioner shall enter into partnerships resulting in the production or distribution of at least one generic form of insulin pursuant to section two hundred eighty-seven of this title.
§ 287. Partnerships; production and distribution of prescription drugs. 1. The commissioner shall enter into partnerships resulting in the production or distribution of at least one generic form of insulin, with the intent that such insulin be made widely available to public and private purchasers, facilities licensed pursuant to article twenty-eight of this chapter, and pharmacies as defined in section six thousand eight hundred two of the education law, as appropriate. Such insulin shall be produced or distributed by a non-profit generic drug manufacturer that is registered with the United States Food and Drug Administration.
2. Each form of insulin produced pursuant to subdivision one of this section shall be made available to providers, patients, and purchasers at a price not to exceed thirty dollars per monthly dose for residents of the state.
§ 288. Proprietary information. Notwithstanding any provision of law to the contrary, all nonpublic information and documents obtained by the department pursuant to this title shall not be required to be disclosed pursuant to article six of the public officers law.
§ 2. This act shall take effect immediately.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.